← back to search

Kathleen Dorris

University of Colorado Denver · US
Area of research
Genetics · Neurology
Research interest
Research interests include Medicine, Temozolomide, Biopsy, Bevacizumab, Cancer research, and Internal medicine.
h-index
citations
322
works
11
NIH funding
primary concept
email

Recent publications

Pediatric Central Nervous System Cancers, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology
Journal of the National Comprehensive Cancer Network 2025cited by 11position: middledoi
Indoximod-based chemo-immunotherapy for pediatric brain tumors: A first-in-children phase I trial
Neuro-Oncology 2023cited by 41position: middledoi
Outcomes of Infants and Young Children With Relapsed Medulloblastoma After Initial Craniospinal Irradiation–Sparing Approaches: An International Cohort Study
Journal of Clinical Oncology 2022cited by 28position: middledoi
LTBK-04. LATE BREAKING ABSTRACT: MEK162 (binimetinib) in children with progressive or recurrent low-grade glioma: a multi-institutional phase II and target validation study
Neuro-Oncology 2022cited by 25position: middledoi
EPCT-01. Pediatric Brain Tumor Consortium (PBTC)-055: A phase I study of trametinib and hydroxychloroquine (HCQ) for BRAF-fusion or Neurofibromatosis type-1 (NF1)-associated pediatric gliomas
Neuro-Oncology 2022cited by 2position: middledoi
Comprehensive molecular characterization of pediatric radiation-induced high-grade glioma
Nature Communications 2021cited by 62position: middledoi
NIMG-31. NON-DIPG PATIENTS ENROLLED IN THE INTERNATIONAL DIPG REGISTRY: HISTOPATHOLOGIC EVALUATION OF CENTRAL NEURO-IMAGING REVIEW
Neuro-Oncology 2020cited by 0position: middledoi
Establishment of patient-derived orthotopic xenograft model of 1q+ posterior fossa group A ependymoma
Neuro-Oncology 2019cited by 17position: middledoi
Prospective feasibility and safety assessment of surgical biopsy for patients with newly diagnosed diffuse intrinsic pontine glioma
Neuro-Oncology 2018cited by 133position: middledoi
PDCT-24. A PHASE I DOSE ESCALATION TRIAL OF THE MEK1/2 INHIBITOR MEK162 (BINIMETINIB) IN CHILDREN WITH LOW-GRADE GLIOMAS AND OTHER RAS-RAF PATHWAY-ACTIVATED TUMORS: INITIAL REPORT
Neuro-Oncology 2017cited by 2position: middledoi
PDCT-20. FEASIBILITY AND SAFETY OF SURGICAL BIOPSY FOR PATIENTS WITH DIPG: PRELIMINARY RESULTS FROM DIPG-BATS
Neuro-Oncology 2017cited by 1position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Sarah Leary · Neurological Surgery1 papers (2017–2017)Clinton F. Stewart · University of Tennessee Health Science Center1 papers (2022–2022)Emily A. McCourt · University of Colorado Denver1 papers (2022–2022)Lindsay Kilburn · Columbia University Irving Medical Center1 papers (2022–2022)Sameer Farouk Sait · Memorial Sloan Kettering Cancer Center1 papers (2022–2022)Etienne Danis · University of Colorado Denver1 papers (2019–2019)Karen Gauvain · Washington University in St. Louis1 papers (2017–2017)Richard Sposto · Radiation Effects Research Foundation1 papers (2017–2017)Angela Pierce · University of Colorado Denver1 papers (2019–2019)Catherine A. Billups · Cancer Research And Biostatistics1 papers (2022–2022)Giles Robinson · Children's Research Hospital1 papers (2022–2022)Eric Prince · University of Denver1 papers (2019–2019) · 1 papers (2017–2017)Mark W. Kieran · NGM Biopharmaceuticals (United States)1 papers (2017–2017)Andrea M. Griesinger · University of Colorado Denver1 papers (2019–2019)Jemily Malvar · Children's Hospital of Los Angeles1 papers (2017–2017) · 1 papers (2022–2022)Sonia Partap · Stanford University1 papers (2022–2022) · 1 papers (2022–2022) · 1 papers (2017–2017)